{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:36:33Z","timestamp":1789601793250,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.ejphar.2009.03.007","type":"journal-article","created":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T08:20:02Z","timestamp":1236759602000},"page":"148-154","source":"Crossref","is-referenced-by-count":59,"title":["Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats"],"prefix":"10.1016","volume":"609","author":[{"given":"Yoshikazu","family":"Fujimori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ishikawa-Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2009.03.007_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrd2420","article-title":"Non-insulin therapies for type 2 diabetes","volume":"6","author":"Ashiya","year":"2007","journal-title":"Nat. Rev., Drug Discov."},{"key":"10.1016\/j.ejphar.2009.03.007_bib2","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0168-8227(98)00043-6","article-title":"Postprandial hyperglycaemia and alpha-glucosidase inhibitors","volume":"40","author":"Baron","year":"1998","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2009.03.007_bib3","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diabetes.47.8.1326","article-title":"Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats","volume":"47","author":"Buckingham","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2009.03.007_bib4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2337\/diabetes.50.8.1863","article-title":"Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance","volume":"50","author":"de Souza","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2009.03.007_bib5","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2337\/diabetes.53.2007.S43","article-title":"The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity","volume":"53","author":"Ferre","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2009.03.007_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2009.03.007_bib7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2165\/00002018-200730120-00005","article-title":"Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus","volume":"30","author":"Hermansen","year":"2007","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejphar.2009.03.007_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1440-1681.2002.03682.x","article-title":"Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats","volume":"29","author":"Ichikawa","year":"2002","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.ejphar.2009.03.007_bib9","first-page":"156","article-title":"Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals","volume":"40","author":"Ikeda","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejphar.2009.03.007_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1248\/bpb.20.354","article-title":"Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-d-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide","volume":"20","author":"Ikenoue","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2009.03.007_bib11","first-page":"285","article-title":"Sodium-glucose cotransporter inhibitors for diabetes","volume":"8","author":"Isaji","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2009.03.007_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2009.03.007_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2009.03.007_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2005.05.042","article-title":"Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat","volume":"519","author":"Minoura","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2009.03.007_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1463-1326.2006.00619.x","article-title":"Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats","volume":"9","author":"Minoura","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2009.03.007_bib16","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00125-006-0316-2","article-title":"Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"49","author":"Nathan","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2009.03.007_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2009.03.007_bib18","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1016\/S0021-9258(19)50557-9","article-title":"Cloning and functional expression of a mammalian Na+\/nucleoside cotransporter. A member of the SGLT family","volume":"267","author":"Pajor","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2009.03.007_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1124\/jpet.107.129825","article-title":"Inhibitor binding in the human renal low- and high-affinity Na+\/glucose cotransporters","volume":"324","author":"Pajor","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2009.03.007_bib20","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2009.03.007_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF03256197","article-title":"Are hypoglycaemia and other adverse effects similar among sulphonylureas?","volume":"21","author":"Salas","year":"2002","journal-title":"Adverse Drug React. Toxicol. Rev."},{"key":"10.1016\/j.ejphar.2009.03.007_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0168-8227(01)00286-8","article-title":"Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients","volume":"55","author":"Vichayanrat","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2009.03.007_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.bjp.0701535","article-title":"Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y","volume":"122","author":"Wang","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2009.03.007_bib24","first-page":"F459","article-title":"Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter","volume":"263","author":"Wells","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2009.03.007_bib25","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am. J. Physiol., Renal Physiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909002040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299909002040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T01:03:17Z","timestamp":1633222997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299909002040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":25,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0014299909002040"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2009.03.007","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}